{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-259636","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2022-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.095170+00:00","generated_at":"2026-06-23T04:45:44.477556+00:00","sec_items":["1.01","3.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology enters amended license deal with Pfizer for ADC platform; pays $8M cash + $10M in stock","bullets":["Pyxis pays Pfizer $8M cash and issues ~2.23M shares ($5M) on closing, plus $5M in shares 180 days later.","Pfizer grants exclusive worldwide rights to FACT platform for ADCs targeting PYX-201 and PYX-203.","Shares are unregistered, relying on Section 4(a)(2) exemption from the Securities Act.","Post-issuance, Pyxis had ~35.1M shares outstanding as of October 6, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-259636","json":"https://secwatch.observer/filing/0001193125-22-259636.json","markdown":"https://secwatch.observer/filing/0001193125-22-259636.md","text":"https://secwatch.observer/filing/0001193125-22-259636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/0001193125-22-259636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/d407930d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:45:44.477556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}